884 related articles for article (PubMed ID: 17091599)
1. [MELD score in prediction of early mortality in patients suffering refractory ascites treated by TIPS].
Fejfar T; Safka V; Hůlek P; Vanásek T; Krajina A; Jirkovský V
Vnitr Lek; 2006 Sep; 52(9):771-6. PubMed ID: 17091599
[TBL] [Abstract][Full Text] [Related]
2. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting.
Schepke M; Roth F; Fimmers R; Brensing KA; Sudhop T; Schild HH; Sauerbruch T
Am J Gastroenterol; 2003 May; 98(5):1167-74. PubMed ID: 12809844
[TBL] [Abstract][Full Text] [Related]
3. MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures.
Montgomery A; Ferral H; Vasan R; Postoak DW
Cardiovasc Intervent Radiol; 2005; 28(3):307-12. PubMed ID: 15886944
[TBL] [Abstract][Full Text] [Related]
4. Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome.
Saad WE; Darwish WM; Davies MG; Waldman DL
J Vasc Interv Radiol; 2010 Feb; 21(2):218-23. PubMed ID: 20123207
[TBL] [Abstract][Full Text] [Related]
5. Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed.
Membreno F; Baez AL; Pandula R; Walser E; Lau DT
J Gastroenterol Hepatol; 2005 Mar; 20(3):474-81. PubMed ID: 15740494
[TBL] [Abstract][Full Text] [Related]
6. [New scoring systems for severity outcome of liver cirrhosis and hepatocellular carcinoma: current issues concerning the Child-Turcotte-Pugh score and the Model of End-Stage Liver Disease (MELD) score].
Lee DH; Son JH; Kim TW
Taehan Kan Hakhoe Chi; 2003 Sep; 9(3):167-79. PubMed ID: 14515034
[TBL] [Abstract][Full Text] [Related]
7. Predictors of early mortality after transjugular intrahepatic portosystemic shunt creation for the treatment of refractory ascites.
Harrod-Kim P; Saad WE; Waldman D
J Vasc Interv Radiol; 2006 Oct; 17(10):1605-10. PubMed ID: 17057001
[TBL] [Abstract][Full Text] [Related]
8. Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis.
Lv XH; Liu HB; Wang Y; Wang BY; Song M; Sun MJ
J Gastroenterol Hepatol; 2009 Sep; 24(9):1547-53. PubMed ID: 19686416
[TBL] [Abstract][Full Text] [Related]
9. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications?
Chung HH; Razavi MK; Sze DY; Frisoli JK; Kee ST; Dake MD; Hellinger JC; Kang BC
J Gastroenterol Hepatol; 2008 Jan; 23(1):95-101. PubMed ID: 18171347
[TBL] [Abstract][Full Text] [Related]
10. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
11. Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: effect on body weight and Child-Pugh score.
Trotter JF; Suhocki PV; Rockey DC
Am J Gastroenterol; 1998 Oct; 93(10):1891-4. PubMed ID: 9772050
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model.
Sun QF; Ding JG; Xu DZ; Chen YP; Hong L; Ye ZY; Zheng MH; Fu RQ; Wu JG; Du QW; Chen W; Wang XF; Sheng JF
J Viral Hepat; 2009 Jul; 16(7):464-70. PubMed ID: 19413694
[TBL] [Abstract][Full Text] [Related]
13. Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score.
Angermayr B; Luca A; König F; Bertolini G; Ploner M; Gridelli B; Ulbrich G; Reiberger T; Bosch J; Peck-Radosavljevic M
Eur J Clin Invest; 2009 Jan; 39(1):65-71. PubMed ID: 19087131
[TBL] [Abstract][Full Text] [Related]
14. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.
Lodato F; Berzigotti A; Lisotti A; Azzaroli F; Mosconi C; Giampalma E; Renzulli M; Cappelli A; Buonfiglioli F; Calvanese C; Zoli M; Golfieri R; Mazzella G
Scand J Gastroenterol; 2012 Dec; 47(12):1494-500. PubMed ID: 22958120
[TBL] [Abstract][Full Text] [Related]
15. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.
Ochs A; Rössle M; Haag K; Hauenstein KH; Deibert P; Siegerstetter V; Huonker M; Langer M; Blum HE
N Engl J Med; 1995 May; 332(18):1192-7. PubMed ID: 7700312
[TBL] [Abstract][Full Text] [Related]
16. Prediction of the prognosis in patients with acute-on-chronic hepatitis using the MELD scoring system.
Yu JW; Wang GQ; Li SC
J Gastroenterol Hepatol; 2006 Oct; 21(10):1519-24. PubMed ID: 16928211
[TBL] [Abstract][Full Text] [Related]
17. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
[TBL] [Abstract][Full Text] [Related]
18. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score.
Ferral H; Gamboa P; Postoak DW; Albernaz VS; Young CR; Speeg KV; McMahan CA
Radiology; 2004 Apr; 231(1):231-6. PubMed ID: 14990811
[TBL] [Abstract][Full Text] [Related]
19. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation.
Gaba RC; Couture PM; Bui JT; Knuttinen MG; Walzer NM; Kallwitz ER; Berkes JL; Cotler SJ
J Vasc Interv Radiol; 2013 Mar; 24(3):411-20, 420.e1-4; quiz 421. PubMed ID: 23312989
[TBL] [Abstract][Full Text] [Related]
20. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
Kim JH; Kim JH; Choi JH; Kim CH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
Scand J Gastroenterol; 2009; 44(3):346-57. PubMed ID: 18991165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
